Tadalafil for lower urinary tract symptoms secondary to benign prostatic hyperplasia.
- Author:
Run-Qiang YUAN
1
Author Information
1. Department of Urology, Zhongshan People's Hospital, Zhongshan, Guangdong 528403, China. yuanrunqiang@yeah.net
- Publication Type:Journal Article
- MeSH:
Carbolines;
therapeutic use;
Humans;
Lower Urinary Tract Symptoms;
drug therapy;
etiology;
Male;
Prostatic Hyperplasia;
complications;
drug therapy;
Retrospective Studies;
Tadalafil;
Treatment Outcome
- From:
National Journal of Andrology
2012;18(12):1147-1151
- CountryChina
- Language:Chinese
-
Abstract:
Tadalafil, as a selective phosphodiesterase type 5 inhibitor (PDE5I), has revolutionized the treatment of erectile dysfunction (ED) in men. Conventional management of lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH), which is highly complex and likely multifactorial, is associated with unwanted side effects. Innovative once-daily tadalafil regimen is effective in treating the signs and symptoms of BPH. In recent trials in men with BPH, tadalafil significantly improved total IPSS over the initial 12 weeks of medication. Moreover, tadalafil is effective in treating both ED and the signs and symptoms of BPH. In this study, we review the current state of this new management strategy for LUTS secondary to BPH, highlighting the published reports on the efficacy and tolerability of tadalafil.
